PDL BioPharma Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/13/2020)
| Balance Sheet | Total Assets | 716,119,000.00 | ROE | – |
| Balance Sheet | Total Equity | 1,141,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -2,463,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -34,906,000.00 | – | – |
| Cashflow | Operating Cash Flow | -32,443,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -0.59 | Div. Yield | – |
| Income | Net Income | -70,411,000.00 | P/E | – |
| Income | Shares Outstanding | 118,631,000.00 | P/B | – |
| Income | Total Revenue | 433,000.00 | P/S | – |
Ratios calculated on: –
Company Description
PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014. It has entered into licensing agreements with numerous entities that are independently developing or have developed humanized antibodies under which it has licensed certain rights under its Queen et al. patents to make, use, sell, offer for sale and import humanized antibodies.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.pdl.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more